Home > Insider Trading > Filing (0001077183-19-000068)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1077183	Neogenomics Inc	NEO	Services-Testing Laboratories (8734)	742897368

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1454941	William Bonello	12701 Commonweatlh Drive Suite 9 Fort Myers FL 33913	Chief Strategy Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-05-06	7,200	$7.52	13,935	No	4	M	Direct
Common Stock	Disposition	2019-05-06	7,200	$23.53	6,735	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2019-05-06	7,200	$0.00	79,963	$7.52

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
72,763	2018-04-28	2022-04-28	No	4	M	Direct

Reported Derivative Holdings

Sec. Name	Sec. Type	Price	Date	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Stock Option (Right to Buy)	$19.60	2020-03-01	2024-03-01	41,167	41,167	Direct
Common Stock	Stock Option (Right to Buy)	$8.03	2019-02-26	2023-02-26	80,334	80,334	Direct

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2024-03-01	41,167	41,167	Direct
2023-02-26	80,334	80,334	Direct

Footnotes

On April 28, 2017, Mr. Bonello was granted an option to purchase shares of NeoGenomics, Inc. common stock. The options vest ratably over the first three anniversary dates of the grant date.
On March 1, 2019, Mr. Bonello was granted an option to purchase shares of NeoGenomics, Inc. common stock. The options vest ratably over the first four anniversary dates of the grant date.
On February 26, 2018, Mr. Bonello was granted an option to purchase shares of NeoGenomics, Inc. common stock. The options vest ratably over the first three anniversary dates of the grant date.